• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Glucagon‐like peptide‐1 (GLP‐1) preserves non‐alcoholic fatty liver disease (NAFLD) through inhibition of the endoplasmic reticulum (ER) stress‐associated pathway
ConclusionGLP‐1 protected against non‐alcoholic fatty liver disease by inactivating the ER stress‐associated apoptosis pathway. In addition, the effect was possibly related to the signaling pathway of ERp46. This article is protected by copyright. All rights reserved.
Source: Hepatology Research - July 4, 2015 Category: Internal Medicine Authors: Na. Ao, Jing Yang, Xiaochen Wang, Jian Du Tags: Original Article Source Type: research

Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway
ConclusionGLP‐1 protected against NAFLD by inactivating the ER stress‐associated apoptosis pathway. In addition, the effect was possibly related to the signaling pathway of ERp46.
Source: Hepatology Research - August 18, 2015 Category: Internal Medicine Authors: Na Ao, Jing Yang, Xiaochen Wang, Jian Du Tags: Original Article Source Type: research

miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1.
CONCLUSION: This study demonstrates that miR-192-5p has a negative regulatory role in lipid synthesis, which is mediated through its direct regulation of SCD-1. PMID: 29290651 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - December 14, 2017 Category: Gastroenterology Authors: Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RX, Zhao ZH, Pan Q, Fan JG Tags: World J Gastroenterol Source Type: research

Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
Abstract Non-alcoholic steatohepatitis (NASH) is a key step in the progression of non-alcoholic fatty liver disease (NAFLD), which causes serious health problems worldwide. The nucleotide-binding oligomerization domain, leucine-rich repeat-containing receptor-containing pyrin domain 3 (NLRP3) inflammasome and pyroptosis play crucial roles in the progression of NASH. Our team has provided clinical evidence of the effects of glucagon-like peptide-1 (GLP-1) on the improvement in liver function and histological resolution of NAFLD. Preliminary work has demonstrated that GLP-1 inhibited NLRP3 inflammasome activation in...
Source: European Journal of Pharmacology - October 4, 2019 Category: Drugs & Pharmacology Authors: Yu X, Hao M, Liu Y, Ma X, Lin W, Xu Q, Zhou H, Shao N, Kuang H Tags: Eur J Pharmacol Source Type: research